Mackenzie Financial Corp Has $756,000 Position in Thermo Fisher Scientific Inc (TMO)

Mackenzie Financial Corp continued to hold its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,920 shares of the medical research company’s stock at the end of the first quarter. Mackenzie Financial Corp’s holdings in Thermo Fisher Scientific were worth $756,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in TMO. Independent Portfolio Consultants Inc. increased its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares during the last quarter. Sharkey Howes & Javer increased its stake in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares during the last quarter. Washington Trust Bank increased its stake in shares of Thermo Fisher Scientific by 0.5% in the first quarter. Washington Trust Bank now owns 2,210 shares of the medical research company’s stock worth $339,000 after buying an additional 10 shares during the last quarter. Beacon Trust Co. increased its stake in shares of Thermo Fisher Scientific by 0.6% in the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock worth $341,000 after buying an additional 12 shares during the last quarter. Finally, Dumont & Blake Investment Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock worth $849,000 after buying an additional 15 shares during the last quarter. 87.60% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Thermo Fisher Scientific Inc (TMO) opened at 172.57 on Friday. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The company has a market cap of $67.32 billion, a PE ratio of 30.06 and a beta of 1.06. The firm’s 50-day moving average is $176.71 and its 200-day moving average is $166.56.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. During the same period in the previous year, the company posted $2.03 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, equities analysts forecast that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is presently 10.45%.

ILLEGAL ACTIVITY NOTICE: “Mackenzie Financial Corp Has $756,000 Position in Thermo Fisher Scientific Inc (TMO)” was originally reported by BNB Daily and is owned by of BNB Daily. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.baseball-news-blog.com/2017/08/19/thermo-fisher-scientific-inc-tmo-stake-maintained-by-mackenzie-financial-corp-updated.html.

Several equities analysts have recently weighed in on the stock. Jefferies Group LLC increased their price objective on shares of Thermo Fisher Scientific from $160.00 to $175.00 and gave the stock a “hold” rating in a research note on Friday, April 28th. Deutsche Bank AG set a $200.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Saturday, June 10th. Wells Fargo & Company reiterated an “outperform” rating and issued a $200.00 price objective (up previously from $195.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 13th. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $210.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. One equities research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus target price of $188.56.

In other news, insider Daniel P. Shine sold 4,688 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $171.88, for a total transaction of $805,773.44. Following the completion of the transaction, the insider now directly owns 29,200 shares of the company’s stock, valued at approximately $5,018,896. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jim P. Manzi sold 11,318 shares of the company’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $172.94, for a total value of $1,957,334.92. Following the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Insiders sold 39,506 shares of company stock valued at $6,834,758 over the last three months. 0.49% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply